Drug Combo Proves Powerful Against Lung Cancer Plainview NY

A two-drug combination treatment in Plainview proved successful in safely slowing advanced non-small cell lung cancer in a recent clinical trial. In the study, a phase 3 trial involving 768 people with the disease, those who had erlotinib (Tarceva) added to their dose of the bevacizumab (Avastin) saw the progression of the disease slow more than if on bevacizumab alone.

Local Companies

Farida P Chaudhri MD
(718) 358-3057
146-01 45th Ave
Flushing, NY
MARC CITRON, MD
(516) 622-6150
2800 Marcus Avenue
New Hyde Park, NY
SAMUEL BANGUG, MD
(718) 657-2706
17013 Hillside Avenue
Jamaica, NY
Jose Paras Barba, MD
718-518-9400
1180 Morris Park Ave
Bronx, NY
Parthasarathy Narasimhan, MD,
718-286-3826
9610 Metropolitan Ave
Forest Hills, NY
Louis Juden Reed
(718) 863-8465
1180 Morris Park Ave
Bronx, NY
BIRJIS AKHUND, MD
(631) 425-2121
180 E Pulaski Road
Huntington Station, NY
LEO WIENER, MD
(516) 742-5353
520 Franklin Avenue
Garden City, NY
HAN XIAO, MD
(908) 542-3300
650 Commack Road
Commack, NY
Charles Carmine Conte, MD
516-487-9454
600 Northern Blvd
Great Neck, NY
Data Provided by:
    

Provided By:

SATURDAY, May 30 (HealthDay News) -- A two-drug combination treatment proved successful in safely slowing advanced non-small cell lung cancer in a recent clinical trial.

In the study, a phase 3 trial involving 768 people with the disease, those who had erlotinib (Tarceva) added to their dose of the bevacizumab (Avastin) saw the progression of the disease slow more than if on bevacizumab alone. People on the combo therapy tolerated the drugs well and survived an average of 4.8 months before the disease grew worse, compared with 3.7 months for those on bevacizumab alone.

Non-small cell lung cancer, often linked to past tobacco use, is the most common of all lung cancers, according to the National Cancer Institute.

"This is the first study to show the addition of erlotinib to maintenance therapy prolongs progression-free survival in patients with advanced non-small cell lung cancer," the study's co-author, Dr. Vincent Miller, a thoracic oncologist at Memorial Sloan-Kettering Cancer Center in New York City, said in a news release from the center. "Knowing which patients will get the greatest benefit from this combination, based on the identification of biomarkers, will be an important next step in this research."

Maintenance therapy aims to slow a disease from getting worse and better the chance of surviving while recovering from stronger chemotherapy treatments, which can weaken and sicken the person.

Miller was to present the findings Saturday at the annual meeting American Society of Clinical Oncology, in Orlando, Fla.

Bevacizumab and erlotinib have previously shown promise in treating non-small cell lung cancer by blocking tumor growth.

More information

The American Cancer Society has more about non-small cell lung cancer.

SOURCE: Memorial Sloan-Kettering Cancer Center, news release, May 30, 2009

Copyright © 2009 ScoutNews, LLC. All rights reserved.

Read Article at HealthDay.com

Related Articles
- Side Effect Of Chemotherapy Drugs Plainview NY
Lung cancer remains the biggest cancer killer, projected to claim 163,510 lives this year. Paclitaxel will be used in the attempt to save the lives of many of these patients. However, one little-known effect of Paclitaxel is that in a subset of these patients there will be up to a fivefold increase in the production of Interleukin. Read on and learn more.
- Exercise for Breast Cancer Survival Plainview NY
- Hormone Therapy for Lung Cancer Plainview NY
- Exercise for Prostate Cancer Plainview NY
- Hormone Therapy for Breast Cancer Plainview NY
- Delayed Prostate Cancer Therapy Plainview NY
- Fungal Infection Treatments Plainview NY
- Risks for Childhood Cancer Survivors Plainview NY
- Genetic Clues for Skin Cancer Therapies Plainview NY